Briacell Therapeutics Corp Stock Return On Equity

BCTXW Stock  USD 0.51  0.01  2.00%   
BriaCell Therapeutics Corp fundamentals help investors to digest information that contributes to BriaCell Therapeutics' financial success or failures. It also enables traders to predict the movement of BriaCell Stock. The fundamental analysis module provides a way to measure BriaCell Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BriaCell Therapeutics stock.
Last ReportedProjected for Next Year
Return On Equity 4.84  5.08 
Return On Equity is likely to climb to 5.08 in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BriaCell Therapeutics Corp Company Return On Equity Analysis

BriaCell Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current BriaCell Therapeutics Return On Equity

    
  -2.06  
Most of BriaCell Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BriaCell Therapeutics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

BriaCell Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for BriaCell Therapeutics is extremely important. It helps to project a fair market value of BriaCell Stock properly, considering its historical fundamentals such as Return On Equity. Since BriaCell Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BriaCell Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BriaCell Therapeutics' interrelated accounts and indicators.
0.79-0.98-0.33-0.010.520.980.020.42-0.440.79-0.080.97-0.56-0.510.69-0.510.69
0.79-0.80.18-0.2-0.10.77-0.260.17-0.130.98-0.20.78-0.2-0.170.24-0.170.24
-0.98-0.80.240.11-0.49-1.00.09-0.430.42-0.830.17-0.990.540.49-0.630.49-0.63
-0.330.180.24-0.79-0.7-0.3-0.86-0.520.650.13-0.71-0.20.780.74-0.880.74-0.88
-0.01-0.20.11-0.790.13-0.070.970.27-0.42-0.170.99-0.19-0.52-0.50.58-0.50.58
0.52-0.1-0.49-0.70.130.540.270.42-0.48-0.070.030.51-0.58-0.540.74-0.540.74
0.980.77-1.0-0.3-0.070.54-0.040.45-0.450.8-0.140.99-0.57-0.520.68-0.520.68
0.02-0.260.09-0.860.970.27-0.040.3-0.45-0.230.93-0.15-0.56-0.530.65-0.530.65
0.420.17-0.43-0.520.270.420.450.3-0.980.260.230.38-0.79-0.80.57-0.80.57
-0.44-0.130.420.65-0.42-0.48-0.45-0.45-0.98-0.21-0.37-0.370.870.88-0.670.88-0.67
0.790.98-0.830.13-0.17-0.070.8-0.230.26-0.21-0.180.81-0.26-0.230.29-0.230.29
-0.08-0.20.17-0.710.990.03-0.140.930.23-0.37-0.18-0.25-0.46-0.450.5-0.450.5
0.970.78-0.99-0.2-0.190.510.99-0.150.38-0.370.81-0.25-0.47-0.420.59-0.420.59
-0.56-0.20.540.78-0.52-0.58-0.57-0.56-0.790.87-0.26-0.46-0.471.0-0.831.0-0.83
-0.51-0.170.490.74-0.5-0.54-0.52-0.53-0.80.88-0.23-0.45-0.421.0-0.781.0-0.78
0.690.24-0.63-0.880.580.740.680.650.57-0.670.290.50.59-0.83-0.78-0.781.0
-0.51-0.170.490.74-0.5-0.54-0.52-0.53-0.80.88-0.23-0.45-0.421.01.0-0.78-0.78
0.690.24-0.63-0.880.580.740.680.650.57-0.670.290.50.59-0.83-0.781.0-0.78
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

BriaCell Total Stockholder Equity

Total Stockholder Equity

(2.26 Million)

BriaCell Therapeutics reported Total Stockholder Equity of (2.38 Million) in 2023
Based on the latest financial disclosure, BriaCell Therapeutics Corp has a Return On Equity of -2.0601. This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

BriaCell Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BriaCell Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BriaCell Therapeutics could also be used in its relative valuation, which is a method of valuing BriaCell Therapeutics by comparing valuation metrics of similar companies.
BriaCell Therapeutics is currently under evaluation in return on equity category among its peers.

BriaCell Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of BriaCell Therapeutics from analyzing BriaCell Therapeutics' financial statements. These drivers represent accounts that assess BriaCell Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BriaCell Therapeutics' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap6.8M77.8M99.9M102.8M92.5M97.1M
Enterprise Value7.0M20.6M58.8M81.5M73.4M77.0M

BriaCell Fundamentals

About BriaCell Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BriaCell Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BriaCell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BriaCell Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.